ArticleJournal of ovarian research2026
Risk prediction model of survival in patients with low-grade serous ovarian cancer: a multicenter Cohort study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeAccurate prognostic prediction remains a significant challenge in the management of low-grade serous ovarian cancer (LGSOC), a rare and molecularly distinct histologic subtype. This study aimed to develop a prediction model visualized by nomogram to predict recurrence and survival outcomes in LGSOC patients.
methodsA retrospective analysis was conducted on patients with LGSOC, using Cox regression to identify factors associated with recurrence and survival for further development of prediction model. The model's accuracy and discriminative ability were assessed with area under the receiver operating characteristic curve (AUC) and calibration curves. The predictive performance of the model and International Federation of Gynecology and Obstetrics (FIGO) staging was compared using the concordance index (C-index), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Additionally, a deep-learning-based prediction model was developed through regression analysis, with performance evaluated via Kaplan-Meier analysis and C-index.
resultsA cohort of 155 patients with LGSOC was analyzed and four independent prognostic factors were identified and incorporated into a Cox regression-based model. The model demonstrated good calibration, as shown by calibration curves. Through internal validation, the model showed superior discriminatory ability over the FIGO staging system, with higher C-indexes for both disease-free survival (0.781 vs. 0.689) and overall survival (0.802 vs. 0.679), which was further confirmed by significant improvements in IDI and NRI. Additionally, the deep learning-based model based on this model was developed to evaluate potential non-linear relationships. This model achieved even higher predictive performance, with C-indexes of 0.907 for disease-free survival and 0.922 for overall survival.
conclusionWe developed a risk prediction model, visualized by a clinically practical nomogram to predict recurrence and survival outcomes in LGSOC patients. Additionally, the deep learning-based prediction model based on neural networks was developed, providing improved prognostic evaluation for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.